Business Wire

GIGABYTE

17.5.2023 03:31:33 CEST | Business Wire | Press release

Share
GIGABYTE to Introduce Leading-Edge AI Solutions and Computers at COMPUTEX 2023, Unveiling “Future of COMPUTING”

GIGABYTE, a leading innovator of computer hardware and server solutions, announces its unprecedented exhibits at COMPUTEX 2023. Resonating its theme “Future of COMPUTING”, GIGABYTE is unveiling its all-around technical achievements, including industry-leading AI/HPC servers, green computing solutions, gaming and creator products, industrial PC, AI smart securities, and autonomous vehicle technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005112/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GIGABYTE to Introduce Leading-Edge AI Solutions and Computers at COMPUTEX 2023, Unveiling “Future of COMPUTING” (Graphic: Business Wire)

Besides product exhibits, GIGABYTE will hold a four-day Tech Talk with speakers from AMD, Ampere, Intel, and NVIDIA, sharing insights about how the future of computing is reshaping the technology landscapes. The exhibition will be held from May 30th to June 2nd on the 1st floor, Taipei Nangang Exhibition Center, Hall 1.

Take the Lead in the AI Era with GIGABYTE’s Trailblazing GPU/HPC Servers

The emergence of ChatGPT and various generative AI applications are making huge waves of industry evolution, driving all-time demand for AI computing servers. At COMPUTEX, GIGABYTE and its subsidiary, Giga Computing, are unveiling a cutting-edge lineup of GPU-accelerated servers and HPC servers. These solutions are aimed at accelerating exascale data analysis, deep learning, machine learning, inferencing, large language models (LLM), and generative AI training tasks, unlocking the unparalleled breakthroughs of AI development.

The latest lineup of GPU/HPC server solutions is powered by the latest CPU platform, GPU accelerator cards, and AI deep learning and inference technologies from leading tech partners. With GIGABYTE’s exclusive density-optimized server design and cooling technology, AI computing servers can achieve superior performance and energy efficiency, allowing enterprises and institutes to become the front-runner in AI competition.

Strike the Goals of Data Center Sustainability with GIGABYTE’s Immersion Cooling Solutions

The advent of AI technology has raised concerns about surging electricity consumption and carbon emissions, leading to the growing demand for data center cooling solutions designed to save power, boost computing performance, and reduce total cost of ownership (TCO). For the first time, GIGABYTE is showcasing three models of immersion cooling tanks and corresponding server series, demonstrating its widely acclaimed green computing solutions at COMPUTEX.

GIGABYTE's immersion cooling solutions have established admirable standards in energy efficiency and cost-effectiveness; therefore, they have been adopted by global semiconductor giants, telecommunication services, and European top research centers. GIGABYTE’s self-developed total solutions include the immersion cooling tanks, server configuration designs, and automatic monitoring and adjustment mechanisms, allowing enterprises and institutions to embrace sustainability and achieve innovation breakthroughs.

Explore the Gaming and Creator Computers with Lightspeed Overlocking

In addition to enterprise solutions, GIGABYTE is exhibiting a comprehensive computer portfolio, including the 2023 Red Dot Design Award-winning AORUS and AERO motherboards, graphics cards, and laptops, as well as STEALTH 500 computer assembly kit that won CES Innovation Award, SSD and large-size 4K monitors. All of these demonstrate GIGABYTE’s technical prowess and exceptional aesthetics. Tech enthusiasts at the booth will be thrilled to explore how GIGABYTE’s computers are pushing the performance beyond the limits and offering immersive experiences.

Grasp the Insights of Industry-Leading AI Trends at GIGABYTE Tech Talk

During the four-day COMPUTEX exhibition, GIGABYTE’s booth is holding Tech Talk sessions with diverse topics. Speakers from technology giants will share first-hand insights of AI advancements and green computing technologies, delivering various perspectives of “Future of COMPUTING” to the audiences.

Visit GIGABYTE’s COMPUTEX event page.
Subscribe to GIGABYTE newsletter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005112/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye